carbamoyl phosphate

(redirected from Carbamylphosphate)

car·ba·mo·yl phos·phate

(kar'bă-mō-il fos'fāt),
A reactive intermediate capable of transferring its carbamoyl group to an acceptor molecule, forming citrulline from ornithine in the urea cycle and ureidosuccinate from aspartate in pyrimidine ring formation.
References in periodicals archive ?
The first three steps are catalyzed by CAD, [4] a trifunctional cytoplasmic enzyme cluster containing carbamylphosphate synthetase, aspartate carbamyltransferase, and dihydroorotase (Fig.
4] Nonstandard abbreviations: CAD, carbamylphosphate synthetase-aspartate carbamyltransferase-dihydroorotase; MS/MS, tandem mass spectrometry; IS, internal standard; N-C-aspartate, N-carbamyl-aspartate; and ESI, electrospray ionization.
14]C]citrulline into [Sigma]A + U by intact cells and on the activities of glutamine synthetase (GS) and carbamylphosphate synthetase (CPSase) in cell-free extracts of YFE leaves from salinized and control plants of both species.
2] on carbamylphosphate synthetase activity in cell-free extracts of YFE leaves of P.
Abbreviations: [Sigma]A + U, total combined pool of arginine plus urea; YFE, young fully expanded; [Sigma]UMP, sum of the uridine nucleotides converted to UMP by acid hydrolysis at 100 [degrees] C; [Psi]s, osmotic potential; CPSase, carbamylphosphate synthetase; CP, carbamylphosphate; GS, glutamine synthetase; OCTase, ornithine carbamyltransferase; ACTase, aspartate carbamyltransferase.
High reactivity of kidney preparations from man, pig, beef, dog and rat for carbamylphosphate hydrolysis.
Ravicti[TM] (glycerol phenylbutyrate), an investigational drug formerly known as HPN-100, is a pre-pro-drug of phenylacetic acid, the active moiety of BUPHENYL([R]), the only branded therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with urea cycle disorders due to deficiencies in carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), and argininosuccinic acid synthetase (AS).
Glycerol phenylbutyrate (HPN-100), an investigational product, is a pre-pro-drug of phenylacetic acid, the active moiety of BUPHENYL([R]), the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle disorders: carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), and argininosuccinic acid synthetase (AS) deficiencies.
BUPHENYL is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS).
HPN-100 (glycerol phenylbutyrate), an investigational product, is a pre-pro-drug of phenylacetic acid, the active moiety of BUPHENYL([R]) (sodium phenylbutyrate) Tablets and Powder, the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle disorders: carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), and argininosuccinic acid synthetase (AS) deficiencies.
HPN-100 (glycerol phenylbutyrate), an investigational product, is a pre-pro-drug of phenylacetic acid, the active moiety of BUPHENYL([R]), the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle disorders: carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), and argininosuccinic acid synthetase (AS) deficiencies.
HPN-100 (glycerol phenylbutyrate), an investigational product, is a pre-pro-drug of phenylacetic acid, the active moiety of BUPHENYL, the only therapy currently FDA-approved as adjunctive therapy for the chronic management of patients with the most prevalent urea cycle disorders: carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), and argininosuccinic acid synthetase (AS) deficiencies.